Previous Close | 13.30 |
Open | 16.45 |
Bid | 17.25 |
Ask | 17.45 |
Strike | 35.00 |
Expire Date | 2022-09-16 |
Day's Range | 16.45 - 16.81 |
Contract Range | N/A |
Volume | |
Open Interest | 1.31k |
Pfizer (PFE) submits NDA to the FDA seeking approval for using its oral antiviral COVID pill in vaccinated and unvaccinated patients at a high risk of developing severe COVID-19 complications.
In anticipation of a new surge of COVID-19 infections later this year, the FDA recommends that COVID-19 vaccine manufacturers develop bivalent booster vaccines that contain the BA.4/BA.5 Omicron subvariants.
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.